Castle Biosciences Acquires Cernostics
October 19, 2021
Castle Biosciences (Nasdaq: CSTL) has completed the acquisition of Cernostics, Inc., a Pittsburgh-based developer of the TissueCypher spatial biology and AI-driven image analysis platform, for approximately $30 million in initial consideration plus up to $50 million in performance-based milestones. The deal brings the TissueCypher Barrett's Esophagus Assay into Castle's portfolio, expanding the company's diagnostics capabilities into the gastrointestinal and oncology markets and adding an estimated ~$1 billion to Castle's U.S. TAM.
- Buyers
- Castle Biosciences, Inc.
- Targets
- Cernostics, Inc.
- Sellers
- Cernostics security holders
- Industry
- Healthcare Services
- Location
- Pennsylvania, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Castle Biosciences Acquires AltheaDx
April 26, 2022
Healthcare Services
Castle Biosciences (Nasdaq: CSTL) completed the acquisition of AltheaDx, a San Diego-based commercial-stage pharmacogenomics company and maker of the IDgenetix mental-health PGx test. Castle paid $65.0 million in initial consideration (split $32.5M cash and $32.5M stock) and may pay up to an additional $75.0 million tied to performance and milestone achievements; AltheaDx becomes a wholly owned subsidiary and IDgenetix now has expanded Medicare coverage for multiple mental health conditions.
-
Axion BioSystems Acquires CytoSMART Technologies
March 21, 2022
Medical Devices
Axion BioSystems has acquired Netherlands-based CytoSMART Technologies, a developer of kinetic live-cell imaging systems and AI-powered image analysis tools. The acquisition expands Axion's product portfolio and capabilities in live-cell imaging to support research in stem cell biology, immuno-oncology, cell-based therapies, and drug discovery.
-
Lantheus Holdings Acquires Cerveau Technologies
February 6, 2023
Pharmaceuticals
Lantheus Holdings, Inc. acquired Knoxville-based Cerveau Technologies, Inc., gaining MK-6240, a clinical-stage F-18 PET imaging agent that targets Tau tangles in Alzheimer's disease. The stock purchase includes upfront and potential milestone payments plus royalty obligations and will expand Lantheus' radiopharmaceutical diagnostic imaging pipeline and research collaborations.
-
Cortexyme Acquires Novosteo to Expand Rare Bone-Disease Pipeline
May 10, 2022
Biotechnology
Cortexyme, Inc. (Nasdaq: CRTX) has acquired privately-held Novosteo, adding Novosteo's bone-targeting therapeutic platform and lead candidate NOV004 to Cortexyme's pipeline. The deal (now closed) gives Novosteo stockholders ~15.5% of the combined company and will see Cortexyme operate under the new name Quince Therapeutics with Novosteo executives joining the leadership team.
-
Fibronostics Acquires Stone Clinical Laboratories
October 27, 2025
Healthcare Services
Fibronostics has completed the acquisition of Stone Clinical Laboratories, LLC, expanding its U.S. laboratory infrastructure to accelerate innovation in non-invasive diagnostics for metabolic and liver diseases (MASH/MASLD). The deal strengthens Fibronostics' R&D and testing capabilities, combining Stone Clinical's laboratory expertise with Fibronostics' proprietary LIVERFASt platform to support biomarker development, clinical validation, and collaborations with biopharma and healthcare partners.
-
TAKE Solutions Acquires DataCeutics Inc.
February 13, 2019
Healthcare Services
TAKE Solutions Ltd. announced the acquisition of North America–based DataCeutics Inc. in an INR 318 crore transaction to strengthen its clinical data science and Functional Service Provider (FSP) capabilities. The deal expands TAKE's clinical services, biostatistics and SAS-based statistical programming capabilities and supports geographic growth in North America, Europe and Asia.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.